anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Despite advances in surgical techniques and care, pancreatoduodenectomy (PD) continues to have high morbidity and mortality rates. Complications such as sepsis, hemorrhage, pulmonary issues, shock, and pancreatic fistula are common postoperative challenges. A key concern in PD outcomes is the high incidence of infectious complications, especially surgical site infections (SSI) and postoperative pancreatic fistula (POPF). Bacteriobilia, or bile contamination with microorganisms, significantly contributes to these infections, increasing the risk of early postoperative complications. The occurrence of SSI in patients who undergo hepatobiliary and pancreatic (HPB) surgeries such as PD is notably higher than that in patients who undergo other surgeries, with rates ranging from 20 to 55%. Recent research by D'Angelica et al. revealed that, compared to cefoxitin, piperacillin/tazobactam considerably lowers the rate of postoperative SSI. However, these findings do not indicate whether extending the duration of antibiotic treatment is beneficial for patients at high risk of bacterial biliary contamination. In scenarios with a high risk of SSI, the specific agents, doses and length of antibiotic therapy remain unexplored. The advantage of prolonged antibiotic prophylaxis following PD has not been established through prospective studies in PD patients following biliary drainage.
METHODS: This is an intergroup FRENCH-ACHBT-SFAR multicenter, open-labelled randomized, controlled, superiority trial comparing 2 broad-spectrum antibiotic (piperacillin/tazobactam) treatment modalities to demonstrate the superiority of 5-day postoperative antibiotic therapy to antibiotic prophylaxis against the occurrence of surgical site infections (SSI) following pancreaticoduodenectomy in patients with preoperative biliary stents. The primary endpoint of this study is the overall SSI rate, defined according to the ACS NSQIP, as a composite of superficial SSI, deep incisional SSI, and organ/space SSI. In addition, we will analyze overall morbidity, antibiotic resistance profiles, the pathogenicity of bacteriological and fungal cocontamination, the impact of complications after bile drainage and neoadjuvant treatment on the bacteriological and fungal profile of biliculture and cost-effectiveness.
CONCLUSION: This FRENCH24-ANIS study aims to evaluate 5-day post-operative antibiotic therapy combined with antibiotic prophylaxis on the occurrence of surgical site infections (SSI) following pancreaticoduodenectomy in patients with preoperative biliary stents.
TRIAL REGISTRATION: ClinicaTrials.gov number, NCT06123169 (Registration Date 08-11-2023); EudraCT number 2021-006991-18; EUCT Number: 2024-515181-14-00.
Women randomized to the control group will receive enhanced usual care (EUC). The World Health Organization (WHO) recommends 8 antenatal visits for a positive pregnancy experience, the number of visits our EUC control group participants will receive (depending on their gestational week). Usual care will also be enhanced by hospital staff receiving additional training in mental health treatment and counseling. Reminder calls were given, provider visits were facilitated (shorter wait times), and transportation to assist participants in attending appointments and medically indicated ultrasounds were paid for (as in the intervention group).
Low levels of vitamin D are associated with a shorter time to first treatment (TTFT) and inferior overall survival in patients with chronic lymphocytic leukemia (CLL). But whether vitamin D supplement affects the clinical course of patients with CLL, remains an open question. In this study, we aimed to retrospectively explore the clinical benefit of vitamin D supplement or one of its analogs, on TTFT and treatment-free survival (TFS) in a large cohort of patients with asymptomatic CLL, who were under watch-and-wait approach. Among the 3474 patients included in the study, 931 patients (26.8%) received either vitamin D supplement or its analog, for a minimum of 6 months. We found that vitamin D supplement was statistically significant for longer TTFT in the young cohort (age ≤65) and was associated with a longer TFS for all ages (P = .004). Among non-vitamin-D users, the median TFS was found to be 84 months, whereas among vitamin D supplement users the median TFS extended to 169 months. In conclusion, our long-term retrospective study demonstrates that the administration of vitamin D to patients with CLL in a watch-and-wait active surveillance is significantly associated with a longer TFS (in any age) and a longer TTFT among young patients (age ≤65). A prospective clinical trial is needed to validate results.
The basic pathogenic reason of an obstructive apnea low ventilation syndrome is the reduction of muscle tension at the time of sleeping, and the reduction results in the repeat narrowness or subsidence of the upper respiratory tract. A mint oil preparation is used by the present invention, and the medicinal preparation is composed of 0.1 to 10% of mint oil and 90 to 99.9% of glycerol or 0.1 to 5% of mint oil, 30 to 35% of glycerol and 60 to 69.9% of distilled water. The mint oil preparation is dropped or sprayed into the oral cavity 15 to 30 minutes before going to bed, which enables the mint oil preparation to slowly penetrate into the pharyngeal part and attach to the surface of the mucous membrane of the pharyngeal part so as to change the surface tension of the mucous membrane of the pharyngeal part and perform the effect of surface lubrication. Thus, the extent of the subsidence of the pharyngeal part of a patient can be relieved, and the mint oil preparation has the effects of relieving inflammation, alleviating pain and resisting infections. Further, the extent of hypoxemia can be relieved, and the effects of maintaining the smoothness of the respiratory tract and treating obstructive sleep apnea can be performed. The present invention has the advantages of outstanding curative effect and no obvious poison and side effect.
The present invention relates to a highly jelly-firming mask pack and a manufacturing method thereof. More specifically, the highly jelly-firming mask pack manufacturing method includes: a first step of spraying an alginic acid solution onto a porous mask pack fabric and drying the same; a second step of folding the dried porous mask pack fabric, inputting the folded porous mask pack fabric in a pouch, and filling the pouch with a saponification substance in a liquid phase; a third step of cooling the substance formed after filling the saponification substance in the pouch in the second step to induce gelation; and a fourth step of sealing the pouch. According to the present invention, the alginic acid component, which is used for inducing and guiding the gelation of the hydrogel, is sprayed onto the porous mask pack fabric in advance to fill the holes on the porous mask pack fabric. Then, the saponification substance is input to the porous mask pack fabric, thereby initiating a crosslinking reaction. The bonding force of the fabric is reinforced to prevent the fabric from being pushed. The gelation is executed without a separate cooling apparatus or a large facility, thereby simplifying the process and significantly reducing the manufacturing cost.
<P>PROBLEM TO BE SOLVED: To provide an improved process for preparing modafinil, whereby it may be isolated in high purity by a single operation of crystallization.  <P>SOLUTION: The present process can be used for producing modafinil which is free of sulfone products by over-oxidation and other byproducts. The invention further provides new crystalline forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil forms II-IV and VI.  <P>COPYRIGHT: (C)2009,JPO&INPIT
PURPOSE:To enable an input according to the instruction of a doctor by converting the form of a medicine in a medical action data storage device to a form suitable for work operation when the form of the medicine is not suitable for the work operation. CONSTITUTION:A converter 5 converts medicine input data in a medical action data storage device 3 to the form suitable for the work operation and returns control to a processor 1. Namely, the medicine input data for one item is taken out from the medical action data storage device 3 and correspondent point master information is taken out from a point master 4. In such a case, when the input amount of the medicine is not in a suitable relation with the number of times for taking the medicine, the medicine is changed to the medicine of the other standard. At such a time, the input amount is converted as well corresponding to the medicine of the other standard. Thus, a result corresponding to a medical business processing is stored in a patient information file 6 and outputted to an output device 7.
Blisters of the skin are treated by applying to the skin over the blister a flexible moisture-containing hydrophilic hydrogel patch that includes a backing support such as paper, cloth or plastic and a water-based hydrogel layer applied to the backing. The hydrogel layer comprises a hydrophilic natural or synthetic polymer to provide body dispersed in water and can be a tacky adhesive. The polymer can comprise any high molecular weight hydrophilic carbohydrate such as karaya, cornstarch, or a kelp gel and/or a synthetic hydrophilic polymer such as polyacrylamide or polyacrylic acid. A humectant such as a polyhydric alcohol, keeps the gel layer moist. A solute such as salt, protein, sugar or an alcohol is dissolved in the water in a quantity sufficient to raise the osmotic pressure enough to maintain the hydrogel layer in a hypertonic state with respect to the blister. The hydrogel which hydrates the normally dry upper layer of skin forms a hydrophilic bridge with the patient's skin that allows fluid to be drawn by osmotic pressure from the blister through the normally dry stratum corneum into the patch. In addition, the hydrogel very quickly significantly dimishes the pain secondary to skin burns and blisters.
AIMS: Patients with haemochromatosis (HFE) are known to have an increased risk of developing hepatocellular carcinoma (HCC). Available data are conflicting on whether such patients have poorer prognosis, and there is lack of data regarding the biology of HFE-HCC. We compared the course of HFE-HCC with a matched non-HFE-HCC control group and examined tumour characteristics using immunohistochemistry.
METHODS: In this tertiary care-based retrospective analysis, 12 patients with HFE and 34 patients with alcohol/non-alcoholic steatohepatitis who underwent initially successful curative HCC therapy with ablation or resection were identified from our registry. Time to tumour progression was compared. Resected liver tissue from a separate cohort of 11 matched patients with HFE-HCC and without HFE-HCC was assessed for the expression of progenitor and epithelial-mesenchymal transition markers using immunohistochemistry.
RESULTS: The median follow-up was 24.39 and 24.28 months for patients with HFE-HCC and those without HFE-HCC, respectively (p>0.05). The mean time to progression was shorter in the HFE group compared with the non-HFE group (12.87 months vs 17.78 months; HR 3.322, p<0.05). Patients with HFE-HCC also progressed to more advanced disease by the end of follow-up (p<0.05). Immunohistochemical analysis of matched HFE-HCC and non-HFE-HCC explants demonstrated increased expression of the cancer stem cell markers EpCAM (epithelial cell adhesion molecule) and EpCAM/SALL4 (spalt-like transcription factor 4) coexpression in HFE-HCC specimens (p<0.05). There was a high frequency of combined tumour subtypes within the HFE cohort.
CONCLUSIONS: This study demonstrates that the clinical course of patients with HFE-HCC is more aggressive and provides the first data indicating that their tumours have increased expression of progenitor markers. These findings suggest patients with HFE-HCC may need to be considered for transplant at an earlier stage.
BACKGROUND: Although cesarean delivery is the most common surgery performed in the United States, prescribing practices for analgesia vary. Strategies to manage postpartum pain have mostly focused on the immediate postpartum period when patients are still admitted to the hospital. At discharge, most providers prescribe a fixed number of opioid tablets. Most patients do not use all the opioids that they are prescribed at hospital discharge. This leads to an excess of opioids in the community, which can ultimately lead to misuse and diversion.
OBJECTIVE: This study aimed to determine whether a transition from universal opioid prescribing to a personalized, patient-specific protocol decreases morphine milligram equivalents prescribed at hospital discharge after cesarean delivery while adequately controlling pain.
STUDY DESIGN: This was a prospective cohort study of patients undergoing cesarean delivery before and after the implementation of a personalized opioid-prescribing practice at the time of hospital discharge. Each patient was prescribed scheduled ibuprofen and acetaminophen, with a prescription for oxycodone tablets equal to 5 times the morphine milligram equivalents used in the 24 hours before discharge, calculated via an electronic order set. The previous traditional cohorts were routinely prescribed 30 tablets of acetaminophen-codeine 300/30 mg. The primary outcome was morphine milligram equivalents prescribed at discharge. A hotline to address pain control issues after discharge was established, and calls, emergency department visits, and readmissions were examined. Statistical analyses was performed using chi-square and Wilcoxon rank-sum test, with a P value of <.05 considered statistically significant.
RESULTS: Overall, 412 patients underwent cesarean delivery in the 6 weeks after initiation of the personalized prescribing protocol and were compared with 367 patients before the change. The median morphine milligram equivalents prescribed at discharge was lower with personalized prescribing (37.5 [interquartile range, 0-75] vs 135 [interquartile range, 135-135]; P<.001). Moreover, 176 patients (43%) were not prescribed opioids at discharge, which was a substantial change as all 367 patients in the traditional cohort received opioids at discharge (P<.001). Of note, 9 hotline phone calls were received; none required additional opioids after a 24-hour trial of scheduled ibuprofen, which none had taken before the call. In addition, 11 patients (2.7%) presented to the emergency department for pain evaluation, of which none required readmission or an outpatient prescription of opioids.
CONCLUSION: A personalized protocol for opioid prescriptions after cesarean delivery decreased the total morphine milligram equivalents and the number of opioid tablets at discharge, without hospital readmissions or need for rescue opioid prescriptions after discharge. Opioids released into our community will be reduced by more than 90,000 tablets per year, without demonstrable adverse effect.
Quetiapine XR will be administered like monotherapy arm. Lithium will be administered twice daily from Day 1 to Day 56.
Make sure the plunger moves smoothly before use. Prime the syringe prior to use by retracting the plunger before injecting the fluid. Alternatively, twist the plunger into the stopper in a clockwise motion until tight. Once tight, continue turning the plunger in a clockwise motion until the stopper rotates freely within the syringe, two or three rotations. The syringe is now primed and suitable for injection.

Before injection of MembraneBlue™ 0.15% perform a 'fluid-air exchange', i.e. filling the entire vitreous cavity with air, to prevent aqeous dilution of MembraneBlue™ 0.15%. MembraneBlue™ 0.15% is carefully applied to the retinal membrane using a blunt cannula attached to the MembraneBlue™ 0.15% syringe, without allowing the cannula to contact or damage the retina. Sufficient staining is expected on contact with the membrane. All excess dye should be removed from the vitreous cavity before performing an air-fluid exchange, to prevent unnecessary spreading of the dye.

MembraneBlue™ 0.15% can also be injected directly in a BSS filled vitreous cavity (instead of injecting under air). Clinical use demonstrated that, after complete vitreous and posterior hyaloid removal, sufficient staining is achieved after 30 seconds of application under BSS.

MembraneBlue™ 0.15% is intended to be applied directly on the areas where membranes could be present, staining any portion of the membrane which comes in contact with the dye. The dye does not penetrate the membrane.
A method for improving the quality and/or increasing the shelf-life of whole blood and red blood cell concentrates during storage thereof comprising manipulating the activities of the key red cell enzymes involved in the biosynthesis and degradation of 2,3-DPG (DPGM, DPGP, PGP) and in regulation of glycolysis (PK and PFK). The enzymes are manipulated, i.e. activated or inhibited, either singly or in combination. Such manipulations are achieved by adding to the whole blood or red blood cell concentrates an effective amount of one or more compounds which primarily inhibit the activity of PK and secondarily inhibit the activity of DPG phosphatase and maintain those of phosphofructokinase, phosphoglycolate phosphatase and DPG mutase. Among the compounds which can be used are L-amino acids, free fatty acids, glycolytic intermediates including analogs and derivatives of phosphoenolpyruvate, and free bases, inhibitors of DPGP as well as structural analogs and derivatives of all of the above compounds. Another compound which can be used to improve the quality of stored blood is a pyrophosphate compound.
The present invention relates to a novel nasal spray containing an aqueous solution or a fluid with an anxiolytic or anticonvulsant substance, wherein the nasal spray is characterized in that with the nasal spray, two sprays with each an equivalent, defined volume of the aqueous solution or liquid of the active agent, can be intranasally administered to a patient and wherein the nasal spray allows for an administration, independent of the spatial orientation of the nasal spray in any position of the patient (standing upright, sitting, lying or in any intermediate position). The nasal spray can be used directly without prior activation. Preferably it is apparent from the nasal spray whether a spray or even a second spray has been made with the nasal spray. Preferably, a spray of the nasal spray can be administered one-handed by the patient or a third person. The active agent in the inventive nasal spray is a benzodiazepine or a GABA-receptor agonist, preferably midazolam or a derivative thereof or a salt of these active agents. The nasal spray according to the present invention may be used for sedation, premedication or treatment of patients with claustrophobia, anxiety disorders or panic attacks or for the treatment of convulsions in CNS diseases, particularly in epileptic seizures or other manifestations of seizures (e.g. febrile convulsions). The invention also relates to a method for hermetically sealing an active agent container for use in supplying an nasal spray in accordance with the invention. The invention also relates to a method of detection by localizing the locally precise administration of an active agent in nasal application, as well as a nasal spray, preferably a bi-dose nasal spray, for which, using the cited method of detection, it has been shown both visually (qualitatively) and quantitatively that an orientation-independent, uniform and locally precise administration of the dose of the active agent onto the nasal mucosa of a patient can be achieved. Also provided is a method for airless and air-tight sealing of an active agent container in accordance with the invention.
The MINISTOP app will be offered to all parents of children at the 2.5/3-year routine visit at primary child healthcare. The child healthcare centers randomly allocated to the basic group will receive the basic implementation strategy package.
A method comprising modulating expression of connexin in cardiac and or bladder and or brain tissue by increasing or decreasing nitric oxide production. That is increasing the coupling between cells or decreasing the coupling between cells by altering the amount of connexin expression between cells via a mechanism related to nitric oxide expression. Specifically a method is described for increasing or decreasing passive current flow between cells by modulating connexin or gap junctions in tissue by increasing or decreasing nitric oxide production. In doing so the invention relates to a method of influencing cardiac conduction by modulating the expression of cross-sectional connexin in cardiac tissue and in turn improving cardiac electrical stability. Specifically the manipulation of connexin/s in cardiac tissue can be used for the treatment of conditions associated with non-uniform electrical conduction in and across cardiac tissue that lead to arrhythmias. The invention may also be useful for the treatment of other conduction abnormalities in other tissues such as in the bladder for the treatment of urinary incontinence and in brain tissue for the treatment of epilepsy and or seizures associated with head trauma. The invention is achieved via the use of nitric oxide donors to increase nitric oxide expression to alter connexin expression and or distribution. Additionally the invention achieves its aims via NOS inhibitors to increase nitric oxide expression to alter connexin expression and or distribution.
INTRODUCTION: Locally advanced non-melanoma skin cancer (NMSC) involving the periosteum or calvarium poses a clinical challenge for patients who are unfit for immunotherapy due to medical comorbidities and/or frailty. This case series aims to investigate outcomes for patients undergoing craniectomy and soft tissue reconstruction.
METHOD: Patients who underwent craniectomy and soft tissue reconstruction for invasive NMSC with calvarium or periosteal invasion between 2016 and 2022 were included. Data, including demographics, operative details, and clinical outcomes, were gathered from Nottingham University Hospitals' digital health record and the histopathology electronic database.
RESULT: Eight patients (average age: 78.4 years, 3 females 5 males) with significant comorbidities and varying degrees of periosteal or bone invasion fulfilled the inclusion criteria. Diagnoses included four squamous cell carcinomas, two basal cell carcinomas, and two pleomorphic dermal sarcomas. Five patients had a history of prior incomplete deep margin excision. The median sizes for soft tissue defect, tumor and bone defect size were 51.83 cm2, 34.63 cm2 and 42.25 cm2, respectively. Intraoperative complications included one dural tear. Four patients underwent local flap reconstruction and with split-thickness skin grafting, four patients underwent free flap reconstruction. Adjuvant radiotherapy was administered to three patients. Complications comprised partial graft loss in two and complete graft loss in one. There was partial flap loss in one case. One patient required subsequent parotidectomy due to regional progression before achieving disease control. All patients achieved lasting locoregional disease control (average follow-up 29.7 months).
CONCLUSION: Craniectomy with soft tissue reconstruction proves to be a safe and effective treatment option in advanced NMSC of the scalp in patients unsuitable for immunotherapy due to frailty or medical co-morbidity.